A5015124959- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Emotion and Mood Recognition
- RNA Research and Splicing
- Medical and Biological Sciences
- RNA and protein synthesis mechanisms
- Streptococcal Infections and Treatments
- Cancer-related Molecular Pathways
- Health and Lifestyle Studies
- Infective Endocarditis Diagnosis and Management
- Monoclonal and Polyclonal Antibodies Research
- Sports and Physical Education Research
- Microtubule and mitosis dynamics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Technology in Education and Healthcare
- Empathy and Medical Education
- Workplace Violence and Bullying
- Neonatal and Maternal Infections
- Medication Adherence and Compliance
- Maternal and Neonatal Healthcare
- Birth, Development, and Health
- Cancer therapeutics and mechanisms
Jagiellonian University
2020-2024
Hospital de Clínicas
2023
Hospital Universitario de Guadalajara
2011-2017
Universidad Nacional de Córdoba
2015
Chartered Institute of Management Accountants
2015
Immune checkpoint blockade is one of the most promising strategies cancer immunotherapy. However, unlike classical targeted therapies, it currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel small-molecule inhibitor at clinically relevant immune checkpoint, PD-1/PD-L1. The compound capable disrupting PD-1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation T cells similarly to while being...
Development of small molecules targeting the PD-L1/PD-1 interface is advancing both in industry and academia, but only a few have reached early-stage clinical trials. Here, we take closer look at general druggability PD-L1 using silico hot spot mapping nuclear magnetic resonance (NMR)-based characterization. We found that conformational elasticity surface strongly influences formation spots. deconstructed several generations known inhibitors into fragments examined their binding properties...
In search of a potent small molecular PD-L1 inhibitor, we designed and synthesized compound based on 2-hydroxy-4-phenylthiophene-3-carbonitrile moiety. Ligand's performance was tested in vitro compared side-by-side with known antagonist proven bioactivity BMS1166. Subsequently, modified both compounds to allow 18F labeling that could be used for PET imaging. Radiolabeling, which is drug development diagnosis, applied investigate the properties those ligands test them against tissue sections...
Screening for small-molecule fragments that can lead to potent inhibitors of protein–protein interactions (PPIs) is often a laborious step as the cannot dissociate targeted PPI due their low μM–mM affinities. Here, we describe an NMR competition assay called w-AIDA-NMR (weak-antagonist induced dissociation assay-NMR), which sensitive weak ligand–protein and be used in initial fragment screening campaigns. By introducing point mutations complex’s protein not by inhibitor, lower effective...
Although heavily studied, the subject of anti-PD-L1 small-molecule inhibitors is still elusive. Here we present a systematic overview principles behind successful inhibitor design on example m-terphenyl scaffold, with particular focus neglected influence solubilizer tag overall affinity toward PD-L1. The developed according to proposed guidelines was characterized through its potency in blocking PD-1/PD-L1 complex formation homogeneous time-resolved fluorescence and cell-based assays. also...
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit degrade the programmed cell death-1/programmed death- ligand 1 (PD-1/PD-L1) complex. Most of displayed excellent inhibitory against PD-1/PD-L1, as assessed by homogenous time-resolved fluorescence (HTRF) binding assay. Among them, compound 3 is one best with an IC50 value 60 nM. Using ex vivo PD-1/PD-L1 blockade line bioassay that expresses human PD-1 PD-L1, we show 4 5...
Objective: In this study we carried out a comparative between posgraduate students conducting master’s degree in the area of health sciences and social sciences, order to examine conceptions learning both groups. Methods: evaluate learning, COLI (Conceptions Learning Inventory) survey modified “ad hoc” component “learning as acquisition competence” is applied. The sample consists total 41 students, 22 belonging master 19 sciences. different items with Likert scale 7 levels then statistical...
ABSTRACT Screening for small-molecule fragments that can lead to potent inhibitors of protein-protein interactions (PPIs) is often a laborious step as the cannot dissociate targeted PPI due their low μM-mM affinities. Here, we describe an NMR competition assay - called w-AIDA-NMR (weak-Antagonist Induced Dissociation Assay-NMR) sensitive weak ligand-protein and which be used in initial fragment screening campaigns. By introducing point mutations complex’s protein not by inhibitor, lower...
<h3>Background</h3> Adding new drugs to the hospital formulary affects outpatient prescribing greatly in secondary care. Ambulatory rivaroxaban was included November 2010 for approved indications only. <h3>Purpose</h3> To assess effect on prescription of ambulatory restricted use indications: prevention venous thromboembolism patients adults undergoing elective hip or knee replacement. <h3>Materials and methods</h3> Analysis data by prescription, supplied Pharmaceutical Inspection Health...
Los oncocitos son células originadas probablemente por transformación metaplásica del epitelio ductal o acinar de parótida y submandibular. Su proliferación puede originar condiciones patológicas que incluyen hiperplasias oncocÃticas adenomatosas multinodulares (HOAM), oncocitomas carcinomas oncocÃticos. tumores oncocÃticos constituyen el 1 % todos los salivales entre 82 90 se desarrollan en la parótida; resto divide glándula submandibular las glándulas menores. Las...
By binding to the spliceosomal protein Snu66, human ubiquitin-like Hub1 is a modulator of spliceosome performance and facilitates alternative splicing. Small molecules that bind would be interest study protein-protein interaction Hub1/Snu66, which linked several pathologies, such as hypercholesterolemia, premature aging, neurodegenerative diseases, cancer. To identify small molecule ligands for Hub1, we used interface analysis, peptide modeling Hub1/Snu66 fragment-based NMR screening....
Abstract Although heavily studied, the subject of anti-PD-L1 small molecular inhibitors is still elusive. Here, we present a systematic overview principles behind successful molecule inhibitor design on example m-terphenyl scaffold with particular focus neglected influence solubilizer tag overall affinity towards PD-L1. The developed according to proposed guidelines was characterized through its potency in blocking PD-1/PD-L1 complex formation HTRF and cell-based assays. also explained based...
Introducción: La hemorragia masiva es la segunda determinante de mortalidad inicial en los enfermos traumatizados.Su tratamiento requiere una reanimación agresiva con sangre o sus componentes Se han postulado nuevos esquemas terapéuticos dentro cuales destaca transfusión masiva.Objetivo: Analizar experiencia aplicación del protocolo pacientes trauma, adultos, que ingresaron el Departamento Emergencia Hospital Clínicas "Dr.Manuel Quintela".Material y métodos: realizó un estudio retrospectivo,...
<h3>Background</h3> The use of oral chemotherapy (OC) is an effective and safe approach in the treatment metastatic castration resistant prostate cancer (MCRP). Abiraterone enzalutamide offer improved patient convenience ease administration. However, patients are now responsible for ensuring optimal adherence to their medication. <h3>Purpose</h3> aim this study was determine abiraterone with MCRP. <h3>Material methods</h3> A retrospective longitudinal carried out from September 2011 March...